Krithika R, Marathe Uttara, Saxena Priti, Ansari Mohd Zeeshan, Mohanty Debasisa, Gokhale Rajesh S
Chemical Biology Group, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110 067, India.
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2069-74. doi: 10.1073/pnas.0507924103. Epub 2006 Feb 3.
Mycobactins are a family of membrane-associated siderophores required for Mycobacterium tuberculosis to adapt to its intracellular habitat. These lipophilic siderophores have been recently shown to directly acquire intracellular iron through lipid trafficking. Despite tremendous progress in understanding the assembly-line enzymology of the siderophore biosynthesis, the genes as well as the mechanistic and biochemical principles involved in producing membrane-associated siderophores have not been investigated. Here, we report a biosynthetic locus that incorporates variety of aliphatic chains on the mycobactin skeleton. Cell-free reconstitution studies demonstrate that these acyl chains are directly transferred from a carrier protein on to the epsilon-amino group of lysine residue by an unidentified Rv1347c gene product. The unsaturation in the lipidic chain is produced by a novel acyl-acyl carrier protein dehydrogenase, which, in contrast to the conventional acyl-CoA dehydrogenases, is involved in the biosynthetic pathway. MbtG protein then performs the final N6-hydroxylation step. Genome-wide analysis revealed homologues of N-acyl transferase and MbtG in other pathogenic bacteria. Because iron plays a key role in the development of infectious diseases, the biosynthetic pathway described here represents an attractive target for developing new antibacterial agents.
分枝杆菌素是结核分枝杆菌适应其细胞内生存环境所需的一类与膜相关的铁载体。最近研究表明,这些亲脂性铁载体可通过脂质转运直接获取细胞内的铁。尽管在理解铁载体生物合成的流水线式酶学方面取得了巨大进展,但参与产生与膜相关铁载体的基因以及其机制和生化原理尚未得到研究。在此,我们报道了一个在分枝杆菌素骨架上整合多种脂肪链的生物合成位点。无细胞重建研究表明,这些酰基链由一个未鉴定的Rv1347c基因产物直接从载体蛋白转移到赖氨酸残基的ε-氨基上。脂质链中的不饱和度由一种新型酰基-酰基载体蛋白脱氢酶产生,与传统的酰基辅酶A脱氢酶不同,该脱氢酶参与生物合成途径。然后,MbtG蛋白执行最后的N6-羟基化步骤。全基因组分析揭示了其他致病细菌中存在N-酰基转移酶和MbtG的同源物。由于铁在传染病的发展中起关键作用,这里描述的生物合成途径是开发新型抗菌剂的一个有吸引力的靶点。